Mode
Text Size
Log in / Sign up

VR-CBTp and CBTp Outcomes for Schizophrenia Spectrum Disorders Paranoia in 254-Person RCTVirtual reality therapy helps some schizophrenia patients more than standard talk therapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that VR-CBTp and CBTp are both suitable, but effects are modest and largely nonsignificant.

This randomized controlled trial enrolled 254 individuals diagnosed with schizophrenia spectrum disorders. The intervention consisted of 10-session virtual reality-based cognitive behavioral therapy for psychosis (VR-CBTp) compared against standard cognitive behavioral therapy for psychosis (CBTp). Follow-up occurred at end-of-treatment. Setting was not reported. Publication type was not reported.

Primary analysis focused on end-of-treatment paranoia. Secondary outcomes included avolition, safety behavior, delusion severity, cognitive biases, negative other-beliefs, age, gender, education, occupation, diagnosis, social anxiety, depression, anhedonia, total negative symptoms, functioning, core beliefs, and interpersonal trauma. Higher baseline avolition, safety behavior, delusion severity, and cognitive biases were associated with end-of-treatment paranoia across treatments. Interaction analyses showed individuals with high avolition improved more in VR-CBTp than CBTp. Participants with moderate-to-high delusion severity improved more in VR-CBTp, whereas those with lower delusion severity showed better outcomes in CBTp.

No demographic or other clinical characteristics were significantly associated with outcome. Moderation analyses revealed interactions for negative other-beliefs, though direction was not reported. Safety data, including adverse events and discontinuations, were not reported. The study is noted as exploratory with modest effects and largely nonsignificant findings.

Both CBTp and VR-CBTp appear suitable for a wide range of individuals with paranoia, highlighting the importance of considering patient preferences and limitations.

Imagine sitting in a safe room, wearing a headset, and facing a situation that usually triggers fear. A therapist guides you through it, step by step. This is virtual reality therapy. For people with schizophrenia who struggle with paranoia, it can feel like a controlled practice ground.

A new study looked at how this approach compares to standard cognitive behavioral therapy for psychosis (CBTp). Both treatments aim to reduce paranoia. But the study asked a deeper question: who benefits most from which therapy?

Paranoia is common in schizophrenia spectrum disorders. It can make people feel unsafe, avoid social contact, and struggle with daily life. Current treatments help many, but not everyone responds the same way. Some people need more engagement to stick with therapy. Others may need a different approach to make progress.

This study explored whether virtual reality could offer a better fit for certain patients. It also asked whether patient traits—like motivation or delusion severity—could predict who does better with VR versus standard talk therapy.

Here’s the twist: the overall effects were modest. Both therapies helped, but no one treatment was clearly better for everyone. The real insight came from looking at who improved more with VR.

The researchers used a simple idea. Think of therapy like a key that opens a door. But not every key fits every lock. Patient traits—like motivation or belief strength—may change how well the key turns. VR might offer a different shape for certain locks.

In this study, VR therapy created a safe space to practice facing fears. Patients could rehearse social situations without real-world risks. This may help those who struggle to engage in traditional talk therapy.

The study included 254 adults with schizophrenia spectrum disorders. All were part of the FaceYourFears trial. Half received standard CBTp (128 people). The other half received VR-CBTp (126 people). Both groups had 10 sessions. Researchers looked at baseline traits and how they related to paranoia at the end of treatment.

They found that higher baseline avolition (lack of motivation), safety behaviors, delusion severity, and cognitive biases were linked to more paranoia after treatment. But the key question was: did VR help certain groups more than standard therapy?

Yes. People with high avolition improved more with VR than with standard therapy. Those with moderate-to-high delusion severity also did better with VR. But people with lower delusion severity actually did better with standard CBTp. This suggests treatment fit matters.

This doesn’t mean VR therapy is better for everyone.

Demographic factors—age, gender, education, occupation—did not predict outcomes. Other clinical traits—like social anxiety, depression, anhedonia, or trauma history—also did not significantly affect results. The main differences came from motivation and delusion severity.

Experts note that this study generates hypotheses, not answers. It suggests VR may engage people who struggle with motivation or stronger delusions. But the effects were modest. Both therapies remain suitable for a wide range of patients. Patient preference should guide treatment choices.

What does this mean for you? If you or a loved one has schizophrenia and struggles with paranoia, talk to your care team about options. VR therapy is not yet widely available, but it is being studied. Ask whether it might fit your needs. Do not stop current treatment without medical guidance.

This study is exploratory. It was not designed to prove VR is superior. The sample was limited to one trial. Future research needs larger groups and longer follow-up. VR equipment and training also add cost and complexity.

What happens next? Researchers will test these ideas in larger trials. They will look at long-term benefits and real-world use. If VR proves helpful for specific groups, it may become part of routine care. For now, it remains a promising tool under study.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: This exploratory study examined baseline characteristics modifying treatment effects on paranoia in individuals diagnosed with schizophrenia spectrum disorders following a 10-session virtual reality-based cognitive behavioral therapy for psychosis (VR-CBTp) or standard CBTp. METHODS: All participants in the FaceYourFears trial were included (=254; CBTp =128; VR-CBTp =126). General linear and logistic regression models examined baseline variables associated with end-of-treatment paranoia. In covariate analyses, regression coefficients quantified associations across treatments. In moderation analyses, interaction terms (randomization x moderator) were tested, with corresponding regression coefficients estimated and assessed at the 25th (low), 50th (medium), and 75th (high) percentiles of continuous variables. RESULTS: Across treatments, higher baseline avolition, safety behavior, delusion severity, and cognitive biases were associated with end-of-treatment paranoia. Moderation analyses revealed interactions for avolition, delusion severity, and negative other-beliefs. Although avolition and delusion severity were associated with poorer outcomes overall, individuals with high avolition and those with moderate-to-high delusion severity improved more in VR-CBTp than CBTp, whereas participants with lower delusion severity showed better outcomes in CBTp. No demographic (age, gender, education, and occupation) or other clinical characteristics (diagnosis, paranoia, social anxiety, depression, anhedonia, total negative symptoms, functioning, core beliefs, or interpersonal trauma) were significantly associated with outcome. CONCLUSIONS: This exploratory study generates hypotheses for future research, including VR-CBTp's potential to engage individuals with high avolition. Given the modest effects and largely nonsignificant findings, both CBTp and VR-CBTp appear suitable for a wide range of individuals with paranoia, highlighting the importance of considering patient preferences.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.